DE602004014484D1 - Verwendung von azetidincarboxamidderivaten in therapie - Google Patents

Verwendung von azetidincarboxamidderivaten in therapie

Info

Publication number
DE602004014484D1
DE602004014484D1 DE602004014484T DE602004014484T DE602004014484D1 DE 602004014484 D1 DE602004014484 D1 DE 602004014484D1 DE 602004014484 T DE602004014484 T DE 602004014484T DE 602004014484 T DE602004014484 T DE 602004014484T DE 602004014484 D1 DE602004014484 D1 DE 602004014484D1
Authority
DE
Germany
Prior art keywords
sup
therapy
carboxamide derivatives
azetidine carboxamide
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004014484T
Other languages
English (en)
Inventor
James E P Davidson
David R V Adams
Michael J Bickerdike
Allan Fletcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Publication of DE602004014484D1 publication Critical patent/DE602004014484D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE602004014484T 2003-05-01 2004-04-29 Verwendung von azetidincarboxamidderivaten in therapie Expired - Fee Related DE602004014484D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310057 2003-05-01
PCT/GB2004/001812 WO2004096209A1 (en) 2003-05-01 2004-04-29 The use of azetidinecarboxamide derivatives in therapy

Publications (1)

Publication Number Publication Date
DE602004014484D1 true DE602004014484D1 (de) 2008-07-31

Family

ID=33397042

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014484T Expired - Fee Related DE602004014484D1 (de) 2003-05-01 2004-04-29 Verwendung von azetidincarboxamidderivaten in therapie

Country Status (16)

Country Link
US (1) US20060276452A1 (de)
EP (1) EP1617839B1 (de)
JP (1) JP2006525297A (de)
KR (1) KR20060017763A (de)
CN (1) CN1780615A (de)
AT (1) ATE398449T1 (de)
AU (1) AU2004233644A1 (de)
BR (1) BRPI0409959A (de)
CA (1) CA2524245A1 (de)
DE (1) DE602004014484D1 (de)
EA (1) EA200501703A1 (de)
MX (1) MXPA05011472A (de)
NO (1) NO20055655L (de)
NZ (1) NZ543322A (de)
WO (1) WO2004096209A1 (de)
ZA (1) ZA200508835B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011670A (es) * 2003-05-01 2005-12-15 Vernalis Res Ltd Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.
CA2613235A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JP2008545008A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP1986638A2 (de) * 2006-02-21 2008-11-05 Ampla Pharmaceuticals Inc. Cb1-antagonisten und inverse agonisten
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US11141404B1 (en) 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
US11795146B2 (en) 2021-10-11 2023-10-24 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (CB1) modulator and methods of use and preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPH03264562A (ja) * 1989-05-22 1991-11-25 Hokuriku Seiyaku Co Ltd ピペリジン誘導体
JP3194355B2 (ja) * 1996-10-24 2001-07-30 宇部興産株式会社 ピペリジン化合物及びその製法
DE69911373T2 (de) * 1998-01-23 2004-07-01 Vernalis Research Ltd., Winnersh Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
FR2805817B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2805810B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
MXPA05011670A (es) * 2003-05-01 2005-12-15 Vernalis Res Ltd Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1.

Also Published As

Publication number Publication date
EA200501703A1 (ru) 2006-06-30
NO20055655D0 (no) 2005-11-30
ZA200508835B (en) 2006-12-27
KR20060017763A (ko) 2006-02-27
CA2524245A1 (en) 2004-11-11
AU2004233644A1 (en) 2004-11-11
ATE398449T1 (de) 2008-07-15
MXPA05011472A (es) 2005-12-12
BRPI0409959A (pt) 2006-04-25
CN1780615A (zh) 2006-05-31
WO2004096209A1 (en) 2004-11-11
JP2006525297A (ja) 2006-11-09
EP1617839B1 (de) 2008-06-18
US20060276452A1 (en) 2006-12-07
NZ543322A (en) 2009-03-31
NO20055655L (no) 2006-01-31
EP1617839A1 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
NO20055655D0 (no) Anvendelse av azetidinkarboksamidderivater i terapi
ATE453620T1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
NZ528851A (en) N-aroyl cyclic amines
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
HK1069339A1 (en) Substituted diketopiperazines as oxytocin antagonists
ATE440603T1 (de) 8-hydroxychinolinderivate
JO2282B1 (en) Oxazole derivatives
ATE384058T1 (de) Thiazolderivate
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
RS20050892A (en) Imidazole derivatives as glutamate receptor antagonists
SE9902267D0 (sv) New compounds
BRPI0517734A (pt) derivados de 1-[(6,7-alcoxiquinoxalinil substituìdo) aminocarbonil]-4- (hetero) arilpiperazina
DE602004015277D1 (de) Substituierte-1-phthalazinamine als vr-1-antagonisten
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
ATE293961T1 (de) Verwendung von hydantoin und seinen derivaten gegen hypalbuminämie
DE69911373D1 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE69902142T2 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
BG105469A (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
TW200511994A (en) Novel compounds and therapeutic uses thereof
UA91693C2 (ru) Арилсульфонилметильные или арилсульфонамидные производные ароматических соединений, пригодные для лечения заболеваний, чувствительных к модулированию дофаминовых рецепторов d3
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee